Clinical trials: Adalimumab
Rheumatoid Arthritis
RESTART C0168Z05 Rheumatoid Arthritis Study
The purpose of this study is to assess the effectiveness of treatment in patients with active rheumatoid arthritis who are having an inadequate response to at least 3 months of treatment with etanercept or adalimumab in addition…
- Trial name
- NCT00714493
- Testing
- Infliximab
- Where
- 76 sites in United States, Austria and 8 more
- Volunteers
- 203 people
- Sponsor
- Centocor Ortho Biotech Services, L.L.C.
Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis
This study is an open-label, randomized, multicenter trial that incorporates a multi-arm design comparing each of 3 non-TNFi (Tumor Necrosis Factor inhibitor) medications to a second TNFi (active control) within a sequential…
- Trial name
- SMART-JIA (NCT06654882)
- Testing
- TNFi (Tumor Necrosis Factor inhibitor) medication, Abatacept, Tocilizumab
- Where
- 7 sites in United States, Germany and 2 more
- Volunteers
- 400 people
- Sponsor
- Duke University
Spondylitis, Ankylosing
A Multicenter Registry of Adalimumab in Chinese Adult Patients With Active Ankylosing Spondylitis
A multicenter registry to explore the clinical outcome of Chinese adult patients with active Ankylosing Spondylitis *AS* treated with adalimumab,prescribed according to the local label,in the real world practice
- Trial name
- NCT01901627
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Peking Union Medical College Hospital
Pharmacokinetics, Safety Issues
A Clinical Study With Adalimumab Biosimilar
The study aims to evaluate the pharmacokinetic profile, safety profile, and immunogenic potential of adalimumab of a new citrate-free formulation of adalimumab (Adalimumab Richmond) [Test Product] vs.
- Trial name
- NCT06291948
- Testing
- Humira® (adalimumab) AC Pen [Reference Product], Adalimumab Richmond [Test Product]
- Where
- Argentina
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Laboratorios Richmond S.A.C.I.F.
Rhematoid Arthritis
An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate
To assess the efficacy of tofacitinib monotherapy or tofacitinib with methotrexate as compared to adalimumab with methotrexate. To compare the efficacy of tofacitinib monotherapy compared to tofacitinib combined with…
- Trial name
- ORAL STRATEGY (NCT02187055)
- Testing
- Tofacitinib with methotrexate, Tofacitinib without methotrexate, Adalimumab with methotrexate
- Where
- 215 sites in United States, Argentina and 23 more
- Volunteers
- 1,152 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 1, Hypoglycemia
Diabetes Islet Preservation Immune Treatment
To assess whether there is a difference in endogenous insulin secretion, measured as stimulated C-peptide secretion (area under the curve during a 4-hour mixed meal tolerance test), at the 1 year visit, for study subjects…
- Conditions
- Diabetes Mellitus, Type 1, Hypoglycemia, Autoimmune Diseases, Diabetes Mellitus
- Trial name
- DIPIT (NCT02586831)
- Testing
- Anti-Thymocyte Globulin (ATG), Interleukin 2, Exenatide
- Sponsor
- Camillo Ricordi and Jay Skyler
Psoriasis
Regulatory T-cells in Psoriasis Patients as Targets for Therapy
The aim of this study is to understand which therapies will suppress effector cells and promote regulatory T cells and To test whether patients with a better response to therapy and longer psoriasis-free periods develop a higher…
- Trial name
- NCT01233583
- Testing
- Dovobet, neotigason, etanercept, adalimumab. infliximab
- Where
- United Kingdom
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Aberdeen
Healthy
Pharmacokinetics and Safety in Healthy Volunteers
Investigate the pharmacokinetics, safety and tolerability of BI695501 and to establish pharmacokinetic similarity of BI 695501 to adalimumab.
- Trial name
- NCT02045979
- Testing
- BI 695501, adalimumab-EU source, adalimumab-US source
- Where
- 3 sites in Belgium, New Zealand
- Volunteers
- 327 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Crohn's Disease
Remission in Subjects With Crohn's Disease, 1 Year Phase
The objectives were: (1) To demonstrate the efficacy of adalimumab in the maintenance of clinical remission up to 56 weeks in participants with Crohn's disease who participated in NCT00055523; (2) To delineate the safety of…
- Trial name
- CLASSICII (NCT00055497)
- Testing
- DB adalimumab 40 mg eow, DB adalimumab 40 mg ew, OL adalimumab 40 mg
- Where
- 43 sites in United States
- Volunteers
- 276 people
- Sponsor
- Abbott
Ulcerative Colitis, Pouchitis
Adalimumab in the Treatment of Chronic Pouchitis
This study wants to investigate the efficiency of biological treatment for chronic pouchitis. Chronic pouchitis is inflammation in a reconstruction after removal of the colon, a pouch.
- Trial name
- ADAP (NCT01670240)
- Testing
- Adalimumab
- Where
- Denmark
- Volunteers
- 13 people
- Sponsor
- Odense University Hospital
Pharmacokinetics, Safety
Study to Compare PK & Safety of Advixa With Humira in Healthy, Adult Subject Followed by Efficacy & Safety Study in RA Patients
Adalimumab is a recombinant monoclonal antibody (IgG1 subclass) against human TNF-α (Tumor Necrosis Factor-alpha). It is an immunosuppressive medication predominantly used to treat rheumatoid arthritis autoimmune disease.
- Conditions
- Pharmacokinetics, Safety, Efficacy, Rheumatoid Arthritis
- Trial name
- ACT (NCT05172817)
- Testing
- Advixa (Adalimumab)
- Where
- Bangladesh
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Institute for Developing Science and Health Initiatives, Bangladesh
Rheumatoid Arthritis (RA)
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)
This study will assess the safety, tolerability, and efficacy of ABBV-3373 in participants with moderately to severely active rheumatoid arthritis (RA) on background methotrexate (MTX) compared with adalimumab.
- Trial name
- NCT03823391
- Testing
- ABBV-3373, Adalimumab
- Where
- 30 sites in United States, Germany and 5 more
- Volunteers
- 48 people
- Sponsor
- AbbVie
Ulcerative Colitis
A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants
The purpose of this retrospective observational cohort study is to assess pregnancy and infant outcomes in three groups: the first is women with ulcerative colitis (UC) who were exposed to ozanimod during pregnancy; the second is…
- Trial name
- NCT06126835
- Testing
- Ozanimod, Conventional therapy, Advanced therapy
- Where
- United States
- Volunteers
- 2,828 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy
That anti-TNF therapy and rituximab therapy are equally effective in treating patients with rheumatoid arthritis who meet the eligibility criteria for biologic therapy in the British Society for Rheumatology guidelines, and have…
- Trial name
- ORBIT (NCT01021735)
- Testing
- etanercept or adalimumab, Rituximab
- Where
- 8 sites in United Kingdom
- Volunteers
- 302 people
- Sponsor
- University of Glasgow
Psoriasis, Vascular Inflammation
Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis
This study is a double-blinded randomized multicenter placebo controlled trial to determine the effect of adalimumab on vascular inflammation (ascending aorta and carotides) in patients with moderate to severe psoriasis.
- Conditions
- Psoriasis, Vascular Inflammation, Coronary Atherosclerosis
- Trial name
- NCT01722214
- Testing
- Adalimumab
- Where
- 5 sites in Canada
- Volunteers
- 107 people
- Sponsor
- Innovaderm Research Inc.
Arthritis, Rheumatoid
The Clinical Efficacy of Immunomodulators in RA Patients
This study includes naive patients and csDMARDs-IR RA patients, treated with different regimens such as Iguratimod combination of different csDMARDs, or csDMARD with TNF inhibitors for 24 weeks.
- Trial name
- NCT05626348
- Testing
- Iguratimod, Methotrexate, Adalimumab Injection
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Qilu Hospital of Shandong University
Pyoderma Gangrenosum
Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum
The purpose of this study is to determine the safety and efficacy of Humira in the treatment of pyoderma gangrenosum.
- Trial name
- NCT00730717
- Testing
- Humira
- Where
- United States
- Sponsor
- Wright State University
Psoriasis
Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- NCT00646191
- Testing
- adalimumab
- Volunteers
- 137 people
- Sponsor
- Abbott
Psoriasis
Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study
The purpose of this study is to determine the safety and efficacy of the use of the combination therapy adalimumab (ADA) every other week (EOW) with methotrexate (MTX) in suboptimal responders to ADA monotherapy.
- Trial name
- CLEAR (NCT02196701)
- Testing
- Adalimumab, Methotrexate
- Volunteers
- 46 people
- Sponsor
- AbbVie
Hidradenitis Suppurativa
Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients
The objective of this study is to assess quality of life (QoL), skin pain, work productivity/activity and health related problems in Swedish patients with moderate to severe HS before and after 6 months treatment with Adalimumab.
- Trial name
- HOPE (NCT02739828)
- Testing
- Adalimumab
- Where
- 11 sites in Sweden
- Volunteers
- 24 people
- Sponsor
- AbbVie